Accéder au contenu
Merck
Toutes les photos(1)

Documents

B1390

Supelco

Bisacodyl

analytical standard, for drug analysis

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C22H19NO4
Numéro CAS:
603-50-9
Poids moléculaire :
361.39
Numéro CE :
210-044-4
Numéro MDL:
MFCD00038039
Code UNSPSC :
41116107
ID de substance PubChem :
329773183
Nomenclature NACRES :
NA.24

Qualité

analytical standard, for drug analysis

Niveau de qualité

100

Technique(s)

HPLC: suitable
gas chromatography (GC): suitable

Application(s)

forensics and toxicology
pharmaceutical (small molecule)
veterinary

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

CC(=O)Oc1ccc(cc1)C(c2ccc(OC(C)=O)cc2)c3ccccn3

InChI

1S/C22H19NO4/c1-15(24)26-19-10-6-17(7-11-19)22(21-5-3-4-14-23-21)18-8-12-20(13-9-18)27-16(2)25/h3-14,22H,1-2H3

Clé InChI

KHOITXIGCFIULA-UHFFFAOYSA-N

Informations sur le gène

human ... CHRM4(1132)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Bisacodyl is a diphenylmethane derivative, mainly used as a stimulant laxative for treating constipation.

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H315,H319,H335

Classification des risques

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organes cibles

Respiratory system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number
104K1274V
104K1274
104K1274
094K1456
074K1796

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 2

1 of 2

Dextromethorphan hydrobromide meets USP testing specifications

Sigma-Aldrich

D9684

Dextromethorphan hydrobromide

Sodium dichloroisocyanurate dihydrate 98.0% (AT)

Sigma-Aldrich

35915

Sodium dichloroisocyanurate dihydrate

Michael A Kamm et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 9(7), 577-583 (2011-03-29)
Although stimulant laxatives have been used for many years to treat patients with constipation, their clinical value has been questioned, and there have been few high-quality trials to assess their efficacy. We tested the efficacy and safety of 4 weeks
Mercedes Ibáñez et al.
Diseases of the colon and rectum, 54(12), 1578-1584 (2011-11-10)
No consensus exists regarding the optimal bowel preparation regimen for patients with poor bowel cleansing at a previous colonoscopy. We investigated the usefulness of an intensive cleansing regimen for repeat colonoscopy after previous failure of bowel preparation. A prospective observational
Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk (2011)
V Giorgio et al.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, 25(1), 70-78 (2012-10-04)
Severe pediatric slow transit constipation (STC) is commonly due to intrinsic colonic neuromuscular disease. We sought to correlate neuromuscular histological phenotypes in pediatric STC with colonic manometric phenotypes using high-resolution manometry (HRM). We tested the hypothesis that failure of motor
Christian Friedrich et al.
Drug metabolism and pharmacokinetics, 26(5), 458-464 (2011-06-24)
The aim of this study was to determine whether administration of the prodrugs bisacodyl (Bisa) and sodium picosulfate (SPS) leads to excretion of their common active metabolite, bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), in breast milk. Two groups of 8 healthy lactating women who
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique